China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant’s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant’s liquid biopsy technology, including the Guardant360, GuardantOMNI, and Guardant360 TissueNext tests, as well as the Guardant Reveal blood-only test for residual disease monitoring.
Partnership Details
Under the agreement, Guardant Health will license its industry-leading liquid biopsy platform to Adicon, enabling the Chinese lab network to offer CGP services for solid tumor patients. Adicon will also gain rights to Guardant Reveal, the first blood-based test for early-stage cancer recurrence monitoring. The partnership aims to accelerate drug development in China by providing biopharma companies with advanced genomic tools.
Company Backgrounds
Founded in 2011, Guardant Health is a global precision oncology leader, leveraging proprietary tests and data analytics to combat cancer. Adicon, a third-party medical lab operator with 26 units in China, will integrate Guardant’s tech into its network to support oncology trials.
Market Impact
The collaboration positions Adicon as a key player in China’s growing genomic testing market, while Guardant expands its international footprint. The deal underscores the rising demand for liquid biopsy solutions in Asia’s clinical research landscape.-Fineline Info & Tech
